Internal tandem duplication of FLT3 (FLT3 ITD) is detectable in one-third of AML patients and point mutations in the tyrosine kinase domain (TKD) in about 10% of AML patients, both of which are considered to be causative mutations of AML. Here, FLT3 is linked to acute myeloid leukemia.